Diagnosis, treatment and outcome of adrenocortical cancer

British Journal of Surgery

Volumn 102, Issue 4, 2015, Pages

  Mihai, R ^a  

^a OXFORD UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; MITOTANE; TUMOR MARKER;

ADJUVANT CHEMOTHERAPY; ADRENAL CORTEX NEOPLASMS; ADRENALECTOMY; ADRENOCORTICAL CARCINOMA; ADULT; CANCER STAGING; CHILD; FEMALE; HUMAN; LAPAROSCOPY; MALE; METABOLISM; METASTASIS RESECTION; MORTALITY; MUTATION; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; STATISTICS AND NUMERICAL DATA; SURVIVAL RATE;

ADRENAL CORTEX NEOPLASMS; ADRENALECTOMY; ADRENOCORTICAL CARCINOMA; ADULT; ANTINEOPLASTIC AGENTS, HORMONAL; CHEMOTHERAPY, ADJUVANT; CHILD; FEMALE; HUMANS; LAPAROSCOPY; MALE; METASTASECTOMY; MITOTANE; MUTATION; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84923104019     PISSN: 00071323     EISSN: 13652168     Source Type: Journal    
DOI: 10.1002/bjs.9743     Document Type: Review

References (115)

1. Stratakis CA. Adrenal cancer in 2013: time to individualize treatment for adrenocortical cancer? Nat Rev Endocrinol 2014; 10: 76-78.
2. Henry JF, Peix JL, Kraimps JL. Positional statement of the European Society of Endocrine Surgeons (ESES) on malignant adrenal tumors. Langenbecks Arch Surg 2012; 397: 145-146.
3. Berruti A, Baudin E, Gelderblom H, Haak HR, Porpiglia F, Fassnacht M et al.; ESMO Guidelines Working Group. Adrenal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012; 23(Suppl 7): vii131-vii138.
4. Else T, Kim AC, Sabolch A, Raymond VM, Kandathil A, Caoili EM et al. Adrenocortical carcinoma. Endocr Rev 2014; 35: 282-326.
5. Kutikov A, Mallin K, Canter D, Wong YN, Uzzo RG. Effects of increased cross-sectional imaging on the diagnosis and prognosis of adrenocortical carcinoma: analysis of the National Cancer Database. J Urol 2011; 186: 805-810.
6. Kerkhofs TM, Verhoeven RH, Van der Zwan JM, Dieleman J, Kerstens MN, Links TP et al. Adrenocortical carcinoma: a population-based study on incidence and survival in the Netherlands since 1993. Eur J Cancer 2013; 49: 2579-2586.
7. Fassnacht M, Johanssen S, Quinkler M, Bucsky P, Willenberg HS, Beuschlein F et al.; German Adrenocortical Carcinoma Registry Group, European Network for the Study of Adrenal Tumors. Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma: proposal for a revised TNM Classification. Cancer 2009; 115: 243-250.
8. Bilimoria KY, Shen WT, Elaraj D, Bentrem DJ, Winchester DJ, Kebebew E et al. Adrenocortical carcinoma in the United States: treatment utilization and prognostic factors. Cancer 2008; 113: 3130-3136.
9. Kebebew E, Reiff E, Duh QY, Clark OH, McMillan A. Extent of disease at presentation and outcome for adrenocortical carcinoma: have we made progress? World J Surg 2006; 30: 872-878.
10. Sturgeon C, Shen WT, Clark OH, Duh QY, Kebebew E. Risk assessment in 457 adrenal cortical carcinomas: how much does tumor size predict the likelihood of malignancy? J Am Coll Surg 2006; 202: 423-430.
11. Johanssen S, Hahner S, Saeger W, Quinkler M, Beuschlein F, Dralle H et al. Deficits in the management of patients with adrenocortical carcinoma in Germany. Deutsch Arztebl Int 2010; 107: 885-891.
12. Ayala-Ramirez M, Jasim S, Feng L, Ejaz S, Deniz F, Busaidy N et al. Adrenocortical carcinoma: clinical outcomes and prognosis of 330 patients at a tertiary care center. Eur J Endocrinol 2013; 169: 891-899.
13. Miller BS, Gauger PG, Hammer GD, Doherty GM. Resection of adrenocortical carcinoma is less complete and local recurrence occurs sooner and more often after laparoscopic adrenalectomy than after open adrenalectomy. Surgery 2012; 152: 1150-1157.
14. Cooper AB, Habra MA, Grubbs EG, Bednarski BK, Ying AK, Perrier ND et al. Does laparoscopic adrenalectomy jeopardize oncologic outcomes for patients with adrenocortical carcinoma? Surg Endosc 2013; 27: 4026-4032.
15. Fassnacht M, Johanssen S, Fenske W, Weismann D, Agha A, Beuschlein F et al.; German ACC Registry Group. Improved survival in patients with stage II adrenocortical carcinoma followed up prospectively by specialized centers. J Clin Endocrinol Metab 2010; 95: 4925-4932.
16. Lombardi CP, Raffaelli M, De Crea C, Boniardi M, De Toma G, Marzano LA et al. Open versus endoscopic adrenalectomy in the treatment of localized (stage I/II) adrenocortical carcinoma: results of a multiinstitutional Italian survey. Surgery 2012; 152: 1158-1164.
17. Watanabe H, Kanematsu M, Goshima S, Kondo H, Kawada H, Noda Y et al. Adrenal-to-liver SUV ratio is the best parameter for differentiation of adrenal metastases from adenomas using 18 F-FDG PET/CT. Ann Nuclear Med 2013; 27: 648-653.
18. Leboulleux S, Deandreis D, Al Ghuzlan A, Auperin A, Goere D, Dromain C et al. Adrenocortical carcinoma: is the surgical approach a risk factor of peritoneal carcinomatosis? Eur J Endocrinol 2010; 162: 1147-1153.
19. Arlt W, Biehl M, Taylor AE, Hahner S, Libe R, Hughes BA et al. Urine steroid metabolomics as a biomarker tool for detecting malignancy in adrenal tumors. J Clin Endocrinol Metab 2011; 96: 3775-3784.
20. Audenet F, Mejean A, Chartier-Kastler E, Roupret M. Adrenal tumours are more predominant in females regardless of their histological subtype: a review. World J Urol 2013; 31: 1037-1043.
21. Gockel I, Kneist W, Heintz A, Beyer J, Junginger T. Endoscopic adrenalectomy: an analysis of the transperitoneal and retroperitoneal approaches and results of a prospective follow-up study. Surg Endosc 2005; 19: 569-573.
22. Lombardi CP, Raffaelli M, Boniardi M, De Toma G, Marzano LA, Miccoli P et al. Adrenocortical carcinoma: effect of hospital volume on patient outcome. Langenbecks Arch Surg 2012; 397: 201-207.
23. Brix D, Allolio B, Fenske W, Agha A, Dralle H, Jurowich C et al.; German Adrenocortical Carcinoma Registry Group. Laparoscopic versus open adrenalectomy for adrenocortical carcinoma: surgical and oncologic outcome in 152 patients. Eur Urol 2010; 58: 609-615.
24. Chadwick D, on behalf of the British Association of Endocrine and Thyroid Surgeons; Kinsman R, Walton P. Fourth National Audit Report; 2012 (http://www.baets.org.uk/wp-content/uploads/2013/05/4th-National-Audit.pdf [accessed 23 November 2014].
25. Tang YZ, Bharwani N, Micco M, Akker S, Rockall AG, Sahdev A. The prevalence of incidentally detected adrenal enlargement on CT. Clin Radiol 2014; 69: e37-e42.
26. Zhang HM, Perrier ND, Grubbs EG, Sircar K, Ye ZX, Lee JE et al. CT features and quantification of the characteristics of adrenocortical carcinomas on unenhanced and contrast-enhanced studies. Clin Radiol 2012; 67: 38-46.
27. Harrison B. The indeterminate adrenal mass. Langenbecks Arch Surg 2012; 397: 147-154.
28. Gust L, Taieb D, Beliard A, Barlier A, Morange I, de Micco C et al. Preoperative 18 F-FDG uptake is strongly correlated with malignancy, Weiss score, and molecular markers of aggressiveness in adrenal cortical tumors. World J Surg 2012; 36: 1406-1410.
29. Nunes ML, Rault A, Teynie J, Valli N, Guyot M, Gaye D et al. 18 F-FDG PET for the identification of adrenocortical carcinomas among indeterminate adrenal tumors at computed tomography scanning. World J Surg 2010; 34: 1506-1510.
30. Tessonnier L, Ansquer C, Bournaud C, Sebag F, Mirallie E, Lifante JC et al. (18)F-FDG uptake at initial staging of the adrenocortical cancers: a diagnostic tool but not of prognostic value. World J Surg 2013; 37: 107-112.
31. 123I]Iodometomidate imaging in adrenocortical carcinoma. J Clin Endocrinol Metab 2013; 98: 2755-2764.
32. Sobin LH, Gospodarowicz MK, Wittekind C. TNM Classification of Malignant Tumours (7th edition). Wiley-Blackwell: Hoboken, 2009.
33. Lughezzani G, Sun M, Perrotte P, Jeldres C, Alasker A, Isbarn H et al. The European Network for the Study of Adrenal Tumors staging system is prognostically superior to the International Union Against Cancer-staging system: a North American validation. Eur J Cancer 2010; 46: 713-719.
34. Lerario AM, Moraitis A, Hammer GD. Genetics and epigenetics of adrenocortical tumors. Mol Cell Endocrinol 2014; 386: 67-84.
35. Waldmann J, Patsalis N, Fendrich V, Langer P, Saeger W, Chaloupka B et al. Clinical impact of TP53 alterations in adrenocortical carcinomas. Langenbecks Arch Surg 2012; 397: 209-216.
36. Herrmann LJ, Heinze B, Fassnacht M, Willenberg HS, Quinkler M, Reisch N et al. TP53 germline mutations in adult patients with adrenocortical carcinoma. J Clin Endocrinol Metab 2012; 97: E476-E485.
37. Raymond VM, Else T, Everett JN, Long JM, Gruber SB, Hammer GD. Prevalence of germline TP53 mutations in a prospective series of unselected patients with adrenocortical carcinoma. J Clin Endocrinol Metab 2013; 98: E119-E125.
38. Heinze B, Herrmann LJ, Fassnacht M, Ronchi CL, Willenberg HS, Quinkler M et al. Less common genotype variants of TP53 polymorphisms are associated with poor outcome in adult patients with adrenocortical carcinoma. Eur J Endocrinol 2014; 170: 707-717.
39. Porpiglia F, Miller BS, Manfredi M, Fiori C, Doherty GM. A debate on laparoscopic versus open adrenalectomy for adrenocortical carcinoma. Horm Cancer 2011; 2: 372-377.
40. Aspinall SR, Imisairi AH, Bliss RD, Scott-Coombes D, Harrison BJ, Lennard TW. How is adrenocortical cancer being managed in the UK? Ann R Coll Surg Engl 2009; 91: 489-493.
41. Grubbs EG, Callender GG, Xing Y, Perrier ND, Evans DB, Phan AT et al. Recurrence of adrenal cortical carcinoma following resection: surgery alone can achieve results equal to surgery plus mitotane. Ann Surg Oncol 2010; 17: 263-270.
42. Hermsen IG, Kerkhofs TM, den Butter G, Kievit J, van Eijck CH, Nieveen van Dijkum EJ et al.; Dutch Adrenal Network. Surgery in adrenocortical carcinoma: importance of national cooperation and centralized surgery. Surgery 2012; 152: 50-56.
43. Jurowich C, Fassnacht M, Kroiss M, Deutschbein T, Germer CT, Reibetanz J. Is there a role for laparoscopic adrenalectomy in patients with suspected adrenocortical carcinoma? A critical appraisal of the literature. Horm Metab Res 2013; 45: 130-136.
44. Carnaille B. Adrenocortical carcinoma: which surgical approach? Langenbecks Arch Surg 2012; 397: 195-199.
45. Mir MC, Klink JC, Guillotreau J, Long JA, Miocinovic R, Kaouk JH et al. Comparative outcomes of laparoscopic and open adrenalectomy for adrenocortical carcinoma: single, high-volume center experience. Ann Surg Oncol 2013; 20: 1456-1461.
46. Porpiglia F, Fiori C, Daffara F, Zaggia B, Bollito E, Volante M et al. Retrospective evaluation of the outcome of open versus laparoscopic adrenalectomy for stage I and II adrenocortical cancer. Eur Urol 2010; 57: 873-878.
47. Miller BS, Ammori JB, Gauger PG, Broome JT, Hammer GD, Doherty GM. Laparoscopic resection is inappropriate in patients with known or suspected adrenocortical carcinoma. World J Surg 2010; 34: 1380-1385.
48. Donatini G, Caiazzo R, Do Cao C, Aubert S, Zerrweck C, El-Kathib Z et al. Long-term survival after adrenalectomy for stage I/II adrenocortical carcinoma (ACC): a retrospective comparative cohort study of laparoscopic versus open approach. Ann Surg Oncol 2014; 21: 284-291.
49. Gaujoux S, Brennan MF. Recommendation for standardized surgical management of primary adrenocortical carcinoma. Surgery 2012; 152: 123-132.
50. Reibetanz J, Jurowich C, Erdogan I, Nies C, Rayes N, Dralle H et al.; German ACC study group. Impact of lymphadenectomy on the oncologic outcome of patients with adrenocortical carcinoma. Ann Surg 2012; 255: 363-369.
51. Tran TB, Liou D, Menon VG, Nissen NN. Surgical management of advanced adrenocortical carcinoma: a 21-year population-based analysis. Am Surg 2013; 79: 1115-1118.
52. Chiche L, Dousset B, Kieffer E, Chapuis Y. Adrenocortical carcinoma extending into the inferior vena cava: presentation of a 15-patient series and review of the literature. Surgery 2006; 139: 15-27.
53. Turbendian HK, Strong VE, Hsu M, Ghossein RA, Fahey TJ III. Adrenocortical carcinoma: the influence of large vessel extension. Surgery 2010; 148: 1057-1064.
54. Mihai R, Iacobone M, Makay O, Moreno P, Frilling A, Kraimps JL et al. Outcome of operation in patients with adrenocortical cancer invading the inferior vena cava - a European Society of Endocrine Surgeons (ESES) survey. Langenbecks Arch Surg 2012; 397: 225-231.
55. Bednarski BK, Habra MA, Phan A, Milton DR, Wood C, Vauthey N et al. Borderline resectable adrenal cortical carcinoma: a potential role for preoperative chemotherapy. World J Surg 2014; 38: 1318-1327.
56. Papotti M, Duregon E, Volante M, McNicol AM. Pathology of the adrenal cortex: a reappraisal of the past 25 years focusing on adrenal cortical tumors. Endocr Path 2014; 25: 35-48.
57. Tissier F, Aubert S, Leteurtre E, Al Ghuzlan A, Patey M, Decaussin M et al. Adrenocortical tumors: improving the practice of the Weiss system through virtual microscopy: a National Program of the French Network INCa-COMETE. Am J Surg Pathol 2012; 36: 1194-1201.
58. Papotti M, Libe R, Duregon E, Volante M, Bertherat J, Tissier F. The Weiss score and beyond - histopathology for adrenocortical carcinoma. Horm Cancer 2011; 2: 333-340.
59. Duregon E, Volante M, Giorcelli J, Terzolo M, Lalli E, Papotti M. Diagnostic and prognostic role of steroidogenic factor 1 in adrenocortical carcinoma: a validation study focusing on clinical and pathologic correlates. Hum Pathol 2013; 44: 822-828.
60. Ragazzon B, Libe R, Assie G, Tissier F, Barreau O, Houdayer C et al. Mass-array screening of frequent mutations in cancers reveals RB1 alterations in aggressive adrenocortical carcinomas. Eur J Endocrinol 2014; 170: 385-391.
61. Zini L, Capitanio U, Jeldres C, Lughezzani G, Sun M, Shariat SF et al. External validation of a nomogram predicting mortality in patients with adrenocortical carcinoma. BJU Int 2009; 104: 1661-1667.
62. Freire DS, Siqueira SA, Zerbini MC, Wajchenberg BL, Correa-Giannella ML, Lucon AM et al. Development and internal validation of an adrenal cortical carcinoma prognostic score for predicting the risk of metastasis and local recurrence. Clin Endocrinol 2013; 79: 468-475.
63. Demeure MJ, Coan KE, Grant CS, Komorowski RA, Stephan E, Sinari S et al. PTTG1 overexpression in adrenocortical cancer is associated with poor survival and represents a potential therapeutic target. Surgery 2013; 154: 1405-1416.
64. Parviainen H, Schrade A, Kiiveri S, Prunskaite-Hyyrylainen R, Haglund C, Vainio S et al. Expression of Wnt and TGF-beta pathway components and key adrenal transcription factors in adrenocortical tumors: association to carcinoma aggressiveness. Pathol Res Pract 2013; 209: 503-509.
65. Chabre O, Libe R, Assie G, Barreau O, Bertherat J, Bertagna X et al. Serum miR-483-5p and miR-195 are predictive of recurrence risk in adrenocortical cancer patients. Endocr Relat Cancer 2013; 20: 579-594.
66. Soon PS, Tacon LJ, Gill AJ, Bambach CP, Sywak MS, Campbell PR et al. miR-195 and miR-483-5p identified as predictors of poor prognosis in adrenocortical cancer. Clin Cancer Res 2009; 15: 7684-7692.
67. Ozata DM, Caramuta S, Velazquez-Fernandez D, Akcakaya P, Xie H, Hoog A et al. The role of microRNA deregulation in the pathogenesis of adrenocortical carcinoma. Endocr Relat Cancer 2011; 18: 643-655.
68. Poli G, Guasti D, Rapizzi E, Fucci R, Canu L, Bandini A et al. Morphofunctional effects of mitotane on mitochondria in human adrenocortical cancer cells. Endocr Relat Cancer 2013; 20: 537-550.
69. Chortis V, Taylor AE, Schneider P, Tomlinson JW, Hughes BA, O'Neil DM et al. Mitotane therapy in adrenocortical cancer induces CYP3A4 and inhibits 5alpha-reductase, explaining the need for personalized glucocorticoid and androgen replacement. J Clin Endocrinol Metab 2013; 98: 161-171.
70. van Erp NP, Guchelaar HJ, Ploeger BA, Romijn JA, Hartigh J, Gelderblom H. Mitotane has a strong and a durable inducing effect on CYP3A4 activity. Eur J Endocrinol 2011; 164: 621-626.
71. Mauclere-Denost S, Leboulleux S, Borget I, Paci A, Young J, Al Ghuzlan A et al. High-dose mitotane strategy in adrenocortical carcinoma: prospective analysis of plasma mitotane measurement during the first 3months of follow-up. Eur J Endocrinol 2012; 166: 261-268.
72. Terzolo M, Baudin AE, Ardito A, Kroiss M, Leboulleux S, Daffara F et al. Mitotane levels predict the outcome of patients with adrenocortical carcinoma treated adjuvantly following radical resection. Eur J Endocrinol 2013; 169: 263-270.
73. Fassnacht M, Allolio B. What is the best approach to an apparently nonmetastatic adrenocortical carcinoma? Clin Endocrinol 2010; 73: 561-565.
74. Polat B, Fassnacht M, Pfreundner L, Guckenberger M, Bratengeier K, Johanssen S. Radiotherapy in adrenocortical carcinoma. Cancer 2009; 115: 2816-2823.
75. Sabolch A, Feng M, Griffith K, Hammer G, Doherty G, Ben-Josef E. Adjuvant and definitive radiotherapy for adrenocortical carcinoma. Int J Radiat Oncol Biol Phys 2011; 80: 1477-1484.
76. Habra MA, Ejaz S, Feng L, Das P, Grubbs EG, Phan A et al. A retrospective cohort analysis of the efficacy of adjuvant radiotherapy after primary surgical resection in patients with adrenocortical carcinoma. J Clin Endocrinol Metab 2013; 98: 192-197.
77. Ho J, Turkbey B, Edgerly M, Alimchandani M, Quezado M, Camphausen K et al. Role of radiotherapy in adrenocortical carcinoma. Cancer J 2013; 19: 288-294.
78. Hermsen IG, Groenen YE, Dercksen MW, Theuws J, Haak HR. Response to radiation therapy in adrenocortical carcinoma. J Endocrinol Invest 2010; 33: 712-714.
79. Schulick RD, Brennan MF. Long-term survival after complete resection and repeat resection in patients with adrenocortical carcinoma. Ann Surg Oncol 1999; 6: 719-726.
80. Erdogan I, Deutschbein T, Jurowich C, Kroiss M, Ronchi C, Quinkler M et al.; German Adrenocortical Carcinoma Study Group. The role of surgery in the management of recurrent adrenocortical carcinoma. J Clin Endocrinol Metab 2013; 98: 181-191.
81. Dy BM, Wise KB, Richards ML, Young WF Jr, Grant CS, Bible KC et al. Operative intervention for recurrent adrenocortical cancer. Surgery 2013; 154: 1292-1299.
82. Terzolo M, Daffara F, Ardito A, Zaggia B, Basile V, Ferrari L et al. Management of adrenal cancer: a 2013 update. J Endocrinol Invest 2014; 37: 207-217.
83. Kerkhofs TM, Baudin E, Terzolo M, Allolio B, Chadarevian R, Mueller HH et al. Comparison of two mitotane starting dose regimens in patients with advanced adrenocortical carcinoma. J Clin Endocrinol Metab 2013; 98: 4759-4767.
84. Fassnacht M, Terzolo M, Allolio B, Baudin E, Haak H, Berruti A et al.; FIRM-ACT Study Group. Combination chemotherapy in advanced adrenocortical carcinoma. N Engl J Med 2012; 366: 2189-2197.
85. Fassnacht M, Kroiss M, Allolio B. Update in adrenocortical carcinoma. J Clin Endocrinol Metab 2013; 98: 4551-4564.
86. 131I]iodometomidate for targeted radionuclide therapy of advanced adrenocortical carcinoma. J Clin Endocrinol Metab 2012; 97: 914-922.
87. Szabo DR, Baghy K, Szabo PM, Zsippai A, Marczell I, Nagy Z et al. Antitumoral effects of 9-cis retinoic acid in adrenocortical cancer. Cell Mol Life Sci 2014; 71: 917-932.
88. Urup T, Pawlak WZ, Petersen PM, Pappot H, Rorth M, Daugaard G. Treatment with docetaxel and cisplatin in advanced adrenocortical carcinoma, a phase II study. Br J Cancer 2013; 108: 1994-1997.
89. Berruti A, Sperone P, Ferrero A, Germano A, Ardito A, Priola AM et al. Phase II study of weekly paclitaxel and sorafenib as second/third-line therapy in patients with adrenocortical carcinoma. Eur J Endocrinol 2012; 166: 451-458.
90. Pezzani R, Rubin B, Redaelli M, Radu C, Barollo S, Cicala MV et al. The antiproliferative effects of ouabain and everolimus on adrenocortical tumor cells. Endocr J 2014; 61: 41-53.
91. Fraenkel M, Gueorguiev M, Barak D, Salmon A, Grossman AB, Gross DJ. Everolimus therapy for progressive adrenocortical cancer. Endocrine 2013; 44: 187-192.
92. Demeure MJ, Bussey KJ, Kirschner LS. Targeted therapies for adrenocortical carcinoma: IGF and beyond. Horm Cancer 2011; 2: 385-392.
93. Naing A, Lorusso P, Fu S, Hong D, Chen HX, Doyle LA et al. Insulin growth factor receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with metastatic adrenocortical carcinoma. Br J Cancer 2013; 108: 826-830.
94. Weigel B, Malempati S, Reid JM, Voss SD, Cho SY, Chen HX et al. Phase 2 trial of cixutumumab in children, adolescents, and young adults with refractory solid tumors: a report from the Children's Oncology Group. Pediatr Blood Cancer 2014; 61: 452-456.
95. Sbiera S, Kroiss M, Thamm T, Beyer M, Majidi F, Kuehner D et al. Survivin in adrenocortical tumors - pathophysiological implications and therapeutic potential. Horm Metab Res 2013; 45: 137-146.
96. O'Sullivan C, Edgerly M, Velarde M, Wilkerson J, Venkatesan AM, Pittaluga S et al. The VEGF inhibitor axitinib has limited effectiveness as a therapy for adrenocortical cancer. J Clin Endocrinol Metab 2014; 99: 1291-1297.
97. De Martino MC, van Koetsveld PM, Feelders RA, Sprij-Mooij D, Waaijers M, Lamberts SW et al. The role of mTOR inhibitors in the inhibition of growth and cortisol secretion in human adrenocortical carcinoma cells. Endocr Relat Cancer 2012; 19: 351-364.
98. De Martino MC, Al Ghuzlan A, Aubert S, Assie G, Scoazec JY, Leboulleux S et al. Molecular screening for a personalized treatment approach in advanced adrenocortical cancer. J Clin Endocrinol Metab 2013; 98: 4080-4088.
99. Nilubol N, Zhang L, Shen M, Zhang YQ, He M, Austin CP et al. Four clinically utilized drugs were identified and validated for treatment of adrenocortical cancer using quantitative high-throughput screening. J Transl Med 2012; 10: 198.
100. Assie G, Antoni G, Tissier F, Caillou B, Abiven G, Gicquel C et al. Prognostic parameters of metastatic adrenocortical carcinoma. J Clin Endocrinol Metab 2007; 92: 148-154.
101. Datrice NM, Langan RC, Ripley RT, Kemp CD, Steinberg SM, Wood BJ et al. Operative management for recurrent and metastatic adrenocortical carcinoma. J Surg Oncol 2012; 105: 709-713.
102. Di Carlo I, Toro A, Sparatore F, Cordio S. Liver resection for hepatic metastases from adrenocortical carcinoma. HPB 2006; 8: 106-109.
103. Ripley RT, Kemp CD, Davis JL, Langan RC, Royal RE, Libutti SK et al. Liver resection and ablation for metastatic adrenocortical carcinoma. Ann Surg Oncol 2011; 18: 1972-1979.
104. Gaujoux S, Al-Ahmadie H, Allen PJ, Gonen M, Shia J, D'Angelica M et al. Resection of adrenocortical carcinoma liver metastasis: is it justified? Ann Surg Oncol 2012; 19: 2643-2651.
105. op den Winkel J, Pfannschmidt J, Muley T, Grunewald C, Dienemann H, Fassnacht M et al. Metastatic adrenocortical carcinoma: results of 56 pulmonary metastasectomies in 24 patients. Ann Thorac Surg 2011; 92: 1965-1970.
106. Kemp CD, Ripley RT, Mathur A, Steinberg SM, Nguyen DM, Fojo T et al. Pulmonary resection for metastatic adrenocortical carcinoma: the National Cancer Institute experience. Ann Thorac Surg 2011; 92: 1195-1200.
107. Dy BM, Strajina V, Cayo AK, Richards ML, Farley DR, Grant CS et al. Surgical resection of synchronously metastatic adrenocortical cancer. Ann Surg Oncol 2014; [Epub ahead of print].
108. Canter DJ, Mallin K, Uzzo RG, Egleston BL, Simhan J, Walton J et al. Association of tumor size with metastatic potential and survival in patients with adrenocortical carcinoma: an analysis of the National Cancer Database. Can J Urol 2013; 20: 6915-6921.
109. Else T, Williams AR, Sabolch A, Jolly S, Miller BS, Hammer GD. Adjuvant therapies and patient and tumor characteristics associated with survival of adult patients with adrenocortical carcinoma. J Clin Endocrinol Metab 2014; 99: 455-461.
110. Kerkhofs TM, Verhoeven RH, Bonjer HJ, van Dijkum EJ, Vriens MR, De Vries J et al.; Dutch Adrenal Network. Surgery for adrenocortical carcinoma in the Netherlands: analysis of the national cancer registry data. Eur J Endocrinol 2013; 169: 83-89.
111. McAteer JP, Huaco JA, Gow KW. Predictors of survival in pediatric adrenocortical carcinoma: a Surveillance, Epidemiology, and End Results (SEER) program study. J Pediatr Surg 2013; 48: 1025-1031.
112. Choong SS, Latiff ZA, Mohamed M, Lim LL, Chen KS, Vengidasan L et al.; Malaysian Society of Paediatric Haematology-Oncology. Childhood adrenocortical carcinoma as a sentinel cancer for detecting families with germline TP53 mutations. Clin Gen 2012; 82: 564-568.
113. Sakoda A, Mushtaq I, Levitt G, Sebire NJ. Clinical and histopathological features of adrenocortical neoplasms in children: retrospective review from a single specialist center. J Pediatr Surg 2014; 49: 410-415.
114. Ahmed AA. Adrenocortical neoplasms in young children: age as a prognostic factor. Ann Clin Lab Sci 2009; 39: 277-282.
115. Fuhrman SA, Lasky LC, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 1982; 6: 655-663.